Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS, Johnson JL, Peloquin C, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00384-19. doi: 10.1128/AAC.00384-19. Print 2019 Jul.

PMID:
31010868
2.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

3.

Lack of penetration of amikacin into saliva of tuberculosis patients.

van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. No abstract available.

4.

Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring.

van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, Bolhuis MS, Alffenaar JC.

Ther Drug Monit. 2018 Feb;40(1):17-37. doi: 10.1097/FTD.0000000000000462. Review.

5.

Membrane Filtration Is Suitable for Reliable Elimination of Mycobacterium tuberculosis from Saliva for Therapeutic Drug Monitoring.

van den Elsen SHJ, van der Laan T, Akkerman OW, van der Zanden AGM, Alffenaar JC, van Soolingen D.

J Clin Microbiol. 2017 Nov;55(11):3292-3293. doi: 10.1128/JCM.01248-17. Epub 2017 Aug 9. No abstract available.

Supplemental Content

Loading ...
Support Center